Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2025-12-17 00:00:00 ET · period of report 2025-12-15 · accession 0001140361-25-045906 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-17 | 2025-12-15 | ROIV | Gline Matthew | CEO, Dir | S - Sale+OE | $21.68 | -1.74M | 18.08M | -9% | -$37.72M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Gline Matthew | CEO, Dir | J - Other | $21.68 | -2.13M | 17.29M | -11% | -$46.19M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Gline Matthew | CEO, Dir | M - OptEx | $12.16 | +3.87M | 18.65M | +26% | +$47.06M |
| DM | 2025-12-17 | 2025-12-15 | ROIV | Gline Matthew | CEO, Dir | M - OptEx | $0.00 | -3.87M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-12-15 | S | D | 943,527 | $21.68 | 18,616,406 | D | — | — | (F1) All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. |
| 2 | Common | Common Shares | 2025-12-15 | J | D | 3,739 | $21.68 | 17,287,081 | D | — | — | (F2) Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. (F1) All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. |
| 3 | Common | Common Shares | 2025-12-15 | M | A | 2,272,852 | $12.68 | 19,559,933 | D | — | — | |
| 4 | Common | Common Shares | 2025-12-15 | M | A | 234,096 | $4.06 | 17,521,177 | D | — | — | |
| 5 | Common | Common Shares | 2025-12-15 | S | D | 230,357 | $21.68 | 17,290,820 | D | — | — | (F1) All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. |
| 6 | Common | Common Shares | 2025-12-15 | M | A | 1,363,711 | $12.68 | 18,650,792 | D | — | — | |
| 7 | Common | Common Shares | 2025-12-15 | S | D | 566,116 | $21.68 | 18,084,676 | D | — | — | (F1) All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. |
| 8 | Common | Common Shares | 2025-12-15 | J | D | 797,595 | $21.68 | 17,287,081 | D | — | — | (F2) Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. (F1) All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. |
| 9 | Common | Common Shares | 2025-12-15 | J | D | 1,329,325 | $21.68 | 17,287,081 | D | — | — | (F2) Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. (F1) All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. |
| 10 | Derivative | Stock Option (Right to Buy) | 2025-12-15 | M | D | 2,272,852 | $0.00 | 0 | D | $12.68 · — to 2026-03-31 | 2,272,852 Common Stock | (F3) Award of stock options to purchase Common Shares that is fully vested. |
| 11 | Derivative | Stock Option (Right to Buy) | 2025-12-15 | M | D | 234,096 | $0.00 | 0 | D | $4.06 · — to 2026-04-19 | 234,096 Common Stock | (F3) Award of stock options to purchase Common Shares that is fully vested. |
| 12 | Derivative | Stock Option (Right to Buy) | 2025-12-15 | M | D | 1,363,711 | $0.00 | 0 | D | $12.68 · — to 2026-03-31 | 1,363,711 Common Stock | (F3) Award of stock options to purchase Common Shares that is fully vested. |